Nvron Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 4.37 M
as on 06-07-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 15.64%
(FY 2023)
- Profit 35.83%
(FY 2023)
- Ebitda 14.54%
(FY 2023)
- Net Worth 23.30%
(FY 2023)
- Total Assets 4.14%
(FY 2023)
About Nvron Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.37 M, as per Ministry of Corporate Affairs (MCA) records.
Subash Nivasgandhi, Radhajanani Sukumar, Jegatheesan Jayaraman, and One other member serve as directors at the Company.
- CIN/LLPIN
U33110TZ2015PLC021561
- Company No.
021561
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nvron Life Science Limited offer?
Nvron Life Science Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Cardiovascular Drugs & Medication, Diabetes Medicine, Organic and Inorganic Solvents, Alcohol Solvents, Brain & Nervous System Drugs, Antiepileptic Drugs, Nutraceuticals & Dietary Supplements, Mineral Supplement.
Who are the key members and board of directors at Nvron Life Science?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subash Nivasgandhi  | Director | 18-Dec-2019 | Current |
| Radhajanani Sukumar | Director | 05-Aug-2019 | Current |
| Jegatheesan Jayaraman | Director | 05-Aug-2019 | Current |
| Subash Kumar | Director | 08-Jul-2015 | Current |
Financial Performance of Nvron Life Science.
Nvron Life Science Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.64% increase. The company also saw a substantial improvement in profitability, with a 35.83% increase in profit. The company's net worth Soared by an impressive increase of 23.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nvron Life Science?
In 2023, Nvron Life Science had a promoter holding of 95.40% and a public holding of 4.60%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nvron Health Care Private LimitedActive 8 years 6 monthsRadhajanani Sukumar and Subash Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nvron Life Science?
Nvron Life Science has a workforce of 4 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nvron Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nvron Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
